The `peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity

By Graner Michael W.  

International Journal of Hyperthermia, Vol. 29, Iss. 5, 2013-08 ,pp. : 380-389

Informa Healthcare

Access to resources Recommend Favorite

Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure

By Mayer-Sonnenfeld Tehila   Har-Noy Michael   Lillehei Kevin O.   Graner Michael W.  

International Journal of Hyperthermia, Vol. 29, Iss. 6, 2013-09 ,pp. : 520-527

Informa Healthcare

Access to resources Recommend Favorite

Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine

By Epple Laura M.  

International Journal of Hyperthermia, Vol. 29, Iss. 5, 2013-08 ,pp. : 390-398

Informa Healthcare

Access to resources Recommend Favorite

Growth Inhibition and Differentiation Induced by Peroxisome Proliferator Activated Receptor Gamma Ligand Rosiglitazone in Human Melanoma Cell Line A375

By  

Medical Oncology, Vol. 23, Iss. 3, 2006-09 ,pp. : 393-402

Humana Press, Inc

Access to resources Recommend Favorite

Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates

By Griffioen Marieke   Borghi Martina   Schrier Peter   Osanto Susanne   Schadendorf Dirk  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 8, 2004-08 ,pp. : 715-722

Springer Publishing Company

Access to resources Recommend Favorite